Delisting riskPopularity #3,854
Synergy CHC (SNYR)
Consumer-health owner of FOCUSfactor supplements and Flat Tummy wellness products.
$0.0905
vs last close0.00 (0.00%)
In millions of USD, except per-share figures
| In millions | Q2 FY23Jun 2023 | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11 | 11 | 13 | 9 | 8 | 7 | 10 | 8 | 8 | 8 | 6 | 5 |
| Cost of revenue | 3 | 3 | 2 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 4 | 2 |
| Gross profit | 8 | 8 | 11 | 7 | 6 | 5 | 7 | 6 | 6 | 6 | 2 | 4 |
| 4 | 6 | 6 | 5 | 4 | 4 | 5 | 4 | 5 | 4 | 9 | 5 | |
| 4 | 6 | 6 | 5 | 4 | 4 | 5 | 4 | 5 | 4 | 9 | 5 | |
| Selling & marketing | 3 | 4 | 5 | 4 | 3 | 3 | 4 | 3 | 3 | 3 | 4 | 2 |
| General & administrative | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 4 | 2 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | 3 | 2 | 4 | 2 | 2 | 1 | 1 | 2 | 2 | 1 | −7 | −1 |
| −1 | −1 | −2 | −1 | −1 | 0 | −1 | −1 | 0 | −1 | −8 | −2 | |
| Interest income | −1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 2 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 2 | 1 | 2 | 2 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −2 | 0 | 7 | 0 |
| Income before tax | 2 | 1 | 3 | 1 | 1 | 1 | 0 | 1 | 2 | 0 | −15 | −3 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | 2 | 1 | 3 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | −15 | −3 |
| Net income | 2 | 1 | 3 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | −15 | −3 |
| EPS, basic | $0.34 | $0.17 | $0.35 | $0.08 | $0.09 | $0.10 | $0.01 | $0.10 | $0.17 | $0.01 | −$1.55 | −$0.23 |
| EPS, diluted | $0.02 | $0.01 | $0.03 | $0.08 | $0.09 | $0.10 | $0.01 | $0.10 | $0.17 | $0.01 | −$1.55 | −$0.23 |
| Weighted average shares, basic | 8 | 8 | 7 | 7 | 8 | 8 | 8 | 9 | 9 | 10 | 10 | 11 |
| Weighted average shares, diluted | 90 | 90 | 90 | 7 | 8 | 8 | 8 | 9 | 9 | 10 | 10 | 11 |
| EBITDA | 3 | 2 | 4 | 2 | 2 | 1 | 2 | 2 | 4 | 1 | −13 | −1 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | 3 | 2 | 4 | 2 | 2 | 1 | 2 | 2 | 4 | 1 | −13 | −1 |